Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

SCH772984

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Otsuka

Drug class:

ERK inhibitor

Related drugs:

‹

›

BRAF mutation	Thyroid Gland Anaplastic Carcinoma	BRAF mutation	Thyroid Gland Anaplastic Carcinoma	dabrafenib + SCH772984 Sensitive: D – Preclinical dabrafenib + SCH772984 Sensitive : D	dabrafenib + SCH772984 Sensitive: D – Preclinical dabrafenib + SCH772984 Sensitive : D
BRAF mutation	Pancreatic Cancer	BRAF mutation	Pancreatic Cancer	SCH772984 Sensitive: D – Preclinical SCH772984 Sensitive : D	SCH772984 Sensitive: D – Preclinical SCH772984 Sensitive : D
KRAS mutation	Melanoma	KRAS mutation	Melanoma	SCH772984 Sensitive: D – Preclinical SCH772984 Sensitive : D	SCH772984 Sensitive: D – Preclinical SCH772984 Sensitive : D
KRAS mutation	Pancreatic Cancer	KRAS mutation	Pancreatic Cancer	SCH772984 Sensitive: D – Preclinical SCH772984 Sensitive : D	SCH772984 Sensitive: D – Preclinical SCH772984 Sensitive : D
BRAF mutation	Melanoma	BRAF mutation	Melanoma	SCH772984 Sensitive: D – Preclinical SCH772984 Sensitive : D	SCH772984 Sensitive: D – Preclinical SCH772984 Sensitive : D
BRAF V600E	Thyroid Gland Carcinoma	BRAF V600E	Thyroid Gland Carcinoma	dasatinib + SCH772984 Sensitive: D – Preclinical dasatinib + SCH772984 Sensitive : D	dasatinib + SCH772984 Sensitive: D – Preclinical dasatinib + SCH772984 Sensitive : D
KRAS G12R	Thyroid Gland Carcinoma	KRAS G12R	Thyroid Gland Carcinoma	dasatinib + SCH772984 Sensitive: D – Preclinical dasatinib + SCH772984 Sensitive : D	dasatinib + SCH772984 Sensitive: D – Preclinical dasatinib + SCH772984 Sensitive : D
HRAS G13R	Thyroid Gland Carcinoma	HRAS G13R	Thyroid Gland Carcinoma	dasatinib + SCH772984 Sensitive: D – Preclinical dasatinib + SCH772984 Sensitive : D	dasatinib + SCH772984 Sensitive: D – Preclinical dasatinib + SCH772984 Sensitive : D
KRAS mutation	Pancreatic Cancer	KRAS mutation	Pancreatic Cancer	SCH772984 + AZD8186 Sensitive: D – Preclinical SCH772984 + AZD8186 Sensitive : D	SCH772984 + AZD8186 Sensitive: D – Preclinical SCH772984 + AZD8186 Sensitive : D
NRAS mutation + BRAF mutation	Melanoma	NRAS mutation + BRAF mutation	Melanoma	SCH772984 Sensitive: D – Preclinical SCH772984 Sensitive : D	SCH772984 Sensitive: D – Preclinical SCH772984 Sensitive : D
NRAS mutation	Melanoma	NRAS mutation	Melanoma	SCH772984 Sensitive: D – Preclinical SCH772984 Sensitive : D	SCH772984 Sensitive: D – Preclinical SCH772984 Sensitive : D